TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02948426

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Monocytes + ACTIMMUNE + SYLATRON
Description: The autologous monocytes cell product in 250ml total volume of investigational combination (monocytes + ACTIMMUNE + SYLATRON) is infused via the intraperitoneal catheter over 30-60 min +/- 10 min every 28 days +/- 7 days until disease progression, limiting toxicity, intercurrent medical issues, or patient withdrawal. Dosing is based on a dose escalation design including an expansion cohort at the maximum tolerated dose (MTD).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Monocytes + ACTIMMUNE + SYLATRON
Description: The autologous monocytes cell product in 250ml total volume of investigational combination (monocytes + ACTIMMUNE + SYLATRON) is infused via the intraperitoneal catheter over 30-60 min +/- 10 min every 28 days +/- 7 days until disease progression, limiting toxicity, intercurrent medical issues, or patient withdrawal. Dosing is based on a dose escalation design including an expansion cohort at the maximum tolerated dose (MTD).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Monocytes + ACTIMMUNE + SYLATRON
Description: The autologous monocytes cell product in 250ml total volume of investigational combination (monocytes + ACTIMMUNE + SYLATRON) is infused via the intraperitoneal catheter over 30-60 min +/- 10 min every 28 days +/- 7 days until disease progression, limiting toxicity, intercurrent medical issues, or patient withdrawal. Dosing is based on a dose escalation design including an expansion cohort at the maximum tolerated dose (MTD).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Monocytes + ACTIMMUNE + SYLATRON
Description: The autologous monocytes cell product in 250ml total volume of investigational combination (monocytes + ACTIMMUNE + SYLATRON) is infused via the intraperitoneal catheter over 30-60 min +/- 10 min every 28 days +/- 7 days until disease progression, limiting toxicity, intercurrent medical issues, or patient withdrawal. Dosing is based on a dose escalation design including an expansion cohort at the maximum tolerated dose (MTD).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Monocytes + ACTIMMUNE + SYLATRON
Description: The autologous monocytes cell product in 250ml total volume of investigational combination (monocytes + ACTIMMUNE + SYLATRON) is infused via the intraperitoneal catheter over 30-60 min +/- 10 min every 28 days +/- 7 days until disease progression, limiting toxicity, intercurrent medical issues, or patient withdrawal. Dosing is based on a dose escalation design including an expansion cohort at the maximum tolerated dose (MTD).
Study: NCT04374422

Intervention type: BEHAVIORAL
Intervention: fsfi survey
Description: sexual behavior Questionaire

Intervention type: BEHAVIORAL
Intervention: fsfi survey
Description: sexual behavior Questionaire
Study: NCT01595841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: 3 mg po od loading dose for two days, then 2 mg po od for thirty days
Study: NCT02569541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium fusidate
Study: NCT01135264

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT
Description: The CBT treatment developed by Ladouceur (Consultant) will serve as control condition (outline of published treatment manual by Ladouceur \& Lachance, 2006. This treatment served as a model for the cognitive-behavioral component in CMBT and has received empirical support in two studies from Ladouceur's lab (Sylvain et al., 1997; Ladouceur et al., 2004). It places strong emphasis on cognitive correction of erroneous beliefs about gambling and also focuses on coping skills training and relapse prevention. CBT also lasts 12 weekly sessions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CMBT
Description: We used the NIMH-funded R21 mechanism to develop and test the CMBT intervention (Wulfert et al., 2003, 2005; 2006). Treatment will be implemented in 12 weekly sessions (3 motivational enhancement sessions, 8 sessions of cognitive-behavioral treatment, 1 session of relapse prevention)
Study: NCT00924586

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ONO-1101
Description: Placebo for one minute IV
Study: NCT05479227

Intervention type: PROCEDURE
Intervention: Management of bile duct injury
Description: There are different options for BDI management, we analyzed their utilization and results
Study: NCT00924586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-1101
Description: 0.125 mg/kg for one minute IV
Study: NCT01493596

Intervention type: DRUG
Group type: OTHER
Intervention: CPP-115
Description: Appropriate amount of drug substance will be dissolved in juice within 3 hours of dosing.

Intervention type: DRUG
Group type: OTHER
Intervention: CPP-115
Description: Appropriate amount of drug substance will be dissolved in juice within 3 hours of dosing.

Intervention type: DRUG
Group type: OTHER
Intervention: CPP-115
Description: Appropriate amount of drug substance will be dissolved in juice within 3 hours of dosing.
Study: NCT02256033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Istradefylline
Description: One 40 mg-tablet administered on Day 1
Study: NCT02572648

Intervention type: OTHER
Intervention: Brain Imaging (Neuroimaging)
Description: Magnetic Resonance Imaging (MR) will be acquired on a research dedicated Siemens 3Tesla TIM TRIO MRI scanner with a 32-channel head coil.The MRI scanning protocol will have scans to measure voxelwise and whole-brain measures of grey matter (GM) volumes through a high resolution T1-weighted (T1W) multi-echo magnetization prepared gradient echo (MEMPRAGE) anatomic scan.~Total time in scanner will be approximately 53 minutes.
Study: NCT02459964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Nasal Spray
Description: Fentanyl nasal spray 100 mcg delivered at time 0 (defined as the time when intranasal Fentanyl spray is administered) with a rescue dose allowed at time 0.5 hour (h)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone Hydrochloride
Description: Hydromorphone hydrochloride 1.5 mg pushed intravenously (IV) at time 0 (defined as the time of completion of opioid IV push) with a rescue dose allowed at time 0.5 hour (h).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone Call
Description: Study nurse to call patient 24 hours after participation to ask about side effects since taking part in the study. The phone call should last about 5 minutes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Phone Call
Description: Study nurse to call patient 24 hours after participation to ask about side effects since taking part in the study. The phone call should last about 5 minutes.
Study: NCT02485964

Intervention type: OTHER
Group type: OTHER
Intervention: Blood draw
Description: One time blood draw at time of consent. Blood will be stored until all subjects have been enrolled and then the enzyme-linked immunospot (ELISPOT) assay will be done to measure the antigen-specific interferon secretion.
Study: NCT02572648

Intervention type: OTHER
Intervention: Brain Imaging (Neuroimaging)
Description: Magnetic Resonance Imaging (MR) will be acquired on a research dedicated Siemens 3Tesla TIM TRIO MRI scanner with a 32-channel head coil.The MRI scanning protocol will have scans to measure voxelwise and whole-brain measures of grey matter (GM) volumes through a high resolution T1-weighted (T1W) multi-echo magnetization prepared gradient echo (MEMPRAGE) anatomic scan.~Total time in scanner will be approximately 53 minutes.

Intervention type: OTHER
Intervention: Cognitive Function Assessment
Description: Cognitive function will be assessed using several batteries; the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), the Controlled Oral Word Association Test (COWA), the Color Trails 1 \& 2, the WAIS-III Digit Span and Letter Number Sequence test, the Stroop Test, and the California Computerized Assessment Package Reaction Time test (CALCAP).

Intervention type: OTHER
Intervention: Cognitive Function Assessment
Description: Cognitive function will be assessed using several batteries; the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), the Controlled Oral Word Association Test (COWA), the Color Trails 1 \& 2, the WAIS-III Digit Span and Letter Number Sequence test, the Stroop Test, and the California Computerized Assessment Package Reaction Time test (CALCAP).
Study: NCT01655446

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mirror Therapy
Description: This protocol includes 1 hour mirror therapy and 0.5 hour functional training in a session. The treatment intensity is 1.5 hours/day, 5 days/week, for 4 weeks. MT focuses on symmetrical bimanual movements and simultaneously observing the mirror visual feedback reflected by the unaffected upper extremity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Rehabilitation
Description: Participants in this group receive a structured protocol based on occupational therapy such as neuro-developmental techniques and task-oriented approach. The treatment dose is matched to RR and MT groups.
Study: NCT00831597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine
Description: 120 mg/m2 IV, Days 1, 2 of Cycles 1-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: 375 mg/m2 IV, Day 1 of Cycles 1-6
Study: NCT04196985

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/MRI
Description: each patient will perform PET/CT and PET/MRI scans in two different days within the interval of less than 2 weeks receiving two different FDG injections. Administered FDG activity for each PET scan will be 4 MBq/Kg up to a maximum of 400 MBq.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: each patient will perform PET/CT and PET/MRI scans in two different days within the interval of less than 2 weeks receiving two different FDG injections. Administered FDG activity for each PET scan will be 4 MBq/Kg up to a maximum of 400 MBq.
Study: NCT06022848

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: occipital nerve stimulator
Description: Quantitative sensory testing
Study: NCT01456780

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loteprednol/tobramycin
Description: Zylet (loteprednol/tobramycin) drops, 1 drop twice a day for 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loteprednol
Description: Eye drops, 1 drop twice a day for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: B+L Advanced Eye Relief Lubricant Drop
Description: Bausch + Lomb (B+L) Advanced Eye Relief Lubricant Drop (Artificial Tears), 1 drop twice a day for 4 weeks.
Study: NCT03155204

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tiotropium pMDI
Description: inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium pMDI
Description: inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium pMDI
Description: inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium pMDI
Description: inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tiotropium pMDI
Description: inhalation
Study: NCT03881657

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reverse Colocated Integrated Care
Description: A reverse colocated integrated care model is one where primary care and preventive services are embedded within a behavioral health service setting.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Behavioral health services without primary care or integrated care services
Study: NCT02718443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VXM01
Description: Oral immunotherapy targeting VEGFR2
Study: NCT02107001

Intervention type: PROCEDURE
Intervention: Lung ultrasound
Description: Lung ultrasonography performed and interpreted by a physician (Pulmonologist or Emergency Physician) possessing specific knowledge in the procedure and a training of at least 100 thoracic ultrasonographies in accordance to a prespecified protocol.
Study: NCT02197871

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: enteral nutrition emulsion
Description: The patient should drink the oral nutritional supplements according to the estimated energy intake and make a record everyday.The patients will be followed up regularly.
Study: NCT04413279

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LipiFlow Thermal Pulsation
Description: To manage patients with dry eye disease secondary to MGD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Intracanalicular Insert, 0.4mg with LipiFlow Thermal Pulsation
Description: to investigate the benefit of managing patients with DED secondary to MGD with a sustained release intracanalicular dexamethasone (0.4 mg) insert in addition to LipiFlow Thermal Pulsation
Study: NCT02579512

Intervention type: OTHER
Intervention: Extra-corporeal ECG signal analysis
Description: The NIA algorithm is similar to the traditional 12-lead ECG equipment. By analyzing patient data, NIA algorithm provides more detailed results compared to traditional 12-lead ECG. Patients with suspected coronary artery disease are conventionally diagnosed and treated by cardiac catheterization. However, cardiac catheterization is invasive procedure. Unless clinical diagnosis is evident before cardiac catheterization, a treadmill exercise test, a nuclear medicine myocardial perfusion test, or a multi-direction coronary CT angiogram is usually performed to increase the accuracy of diagnosis. But these examinations are not accessible to all patients, and are time-consuming and costly.
Study: NCT03511248

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nitrate-rich Beetroot Juice
Description: The beetroot juice contains approximately 100kcal per 100mL of juice, equivalent to a glass of orange juice; the volume of juice per day for the study is 70mL. Volunteers will be informed that an average woman weighing 65kg should not consume more than 2000kcal per day, and an average man of 75kg not more than 2500kcal per day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nitrate-deplete Beetroot Juice
Description: The beetroot juice contains approximately 100kcal per 100mL of juice, equivalent to a glass of orange juice; the volume of juice per day for the study is 70mL. Volunteers will be informed that an average woman weighing 65kg should not consume more than 2000kcal per day, and an average man of 75kg not more than 2500kcal per day.
Study: NCT01473628

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Observation
Description: Undergo observation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study: NCT00002556

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carmustine
Description: Given IV
Study: NCT01493596

Intervention type: DRUG
Group type: OTHER
Intervention: CPP-115
Description: Appropriate amount of drug substance will be dissolved in juice within 3 hours of dosing.

Intervention type: DRUG
Group type: OTHER
Intervention: CPP-115
Description: Appropriate amount of drug substance will be dissolved in juice within 3 hours of dosing.

Intervention type: DRUG
Group type: OTHER
Intervention: CPP-115
Description: Appropriate amount of drug substance will be dissolved in juice within 3 hours of dosing.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: An equal volume of water mixed with juice will be administered.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: An equal volume of water mixed with juice will be administered.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: An equal volume of water mixed with juice will be administered.
Study: NCT00002556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: melphalan
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa-2b
Description: Given SC

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03683472

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unwinding Anxiety Phone App
Description: The Unwinding Anxiety program focuses on teaching individuals 1) to understand how anxious worry is developed and perpetuated through reinforcement learning, 2) how to recognize these worry habit loops and 3) how to bring mindful awareness to moments of worry such that they can uncouple feelings of anxiety from reactive worry thinking and ride out habitual mind states that perpetuate and reinforce anxiety
Study: NCT02933320

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BI-1206 single agent dose escalation phase
Description: BI-1206 single agent dose escalation phase to determine the MTD or maximum administered dose (MAD) and recommended Phase II dose (RP2D) for evaluation of BI-1206.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Combination of BI-1206 with rituximab escalation phase
Description: An investigation of combination treatment of BI-1206 with rituximab.
Study: NCT01655446

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Robotic Rehabilitation
Description: This protocol includes 5 to 10 min of warm-up, 1 hr of RR, and 15 to 20 min of functional activities training. The treatment intensity is 1.5 hours/day, 5days/week for 4 consecutive weeks. The RR session uses the robot-assisted arm trainer, Bi-Manu-Track (Reha-Stim Co., Berlin, Germany).
Study: NCT01493596

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: An equal volume of water mixed with juice will be administered.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: An equal volume of water mixed with juice will be administered.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: An equal volume of water mixed with juice will be administered.
Study: NCT03423667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: N-acetylcysteine (1200 mg) administered twice a day during 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactose powder
Description: Placebo comparator.
Study: NCT03182751

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid (TXA)
Description: Intravenously via bolus dose of 1g over ten minutes and an additional 1g over the subsequent 8 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Looks exactly like the study drug, but it contains no active ingredient
Study: NCT00196820

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Study: NCT03324217

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental Practise
Description: They made a mental task to produce a neurophysiological activation of the brain areas related to the planning and execution of voluntary movement in a manner that resembles how the action is performed in reality in combination with real exercises.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mental Practise
Description: They made a mental task to produce a neurophysiological activation of the brain areas related to the planning and execution of voluntary movement in a manner that resembles how the action is performed in reality in combination with real exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental Practise
Description: They made a mental task to produce a neurophysiological activation of the brain areas related to the planning and execution of voluntary movement in a manner that resembles how the action is performed in reality in combination with real exercises.
Study: NCT01175473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide (AVE0010)
Description: Self administered by subcutaneous injections once daily 30 minutes before breakfast.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pen auto-injector

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Self administered by subcutaneous injections once daily 30 minutes before breakfast.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pre-filled pen injector

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin to be continued at stable dose (1.5 gram per day) up to Week 4.
Study: NCT02933320

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BI-1206 single agent expansion phase
Description: BI-1206 single agent expansion phase at the RP2D.
Study: NCT01175473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin to be continued at stable dose (1.5 gram per day) up to Week 4.
Study: NCT03864185

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab (genetical recombination)
Description: Administer 375 mg/m2 of rituximab (genetical recombination) IV infusion once weekly for 4 doses.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab (genetical recombination)
Description: Administer 375 mg/m2 of rituximab (genetical recombination) IV infusion once weekly for 4 doses.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administer placebo IV infusion once weekly for 4 doses.
Study: NCT01655446

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Robotic rehabilitation with FES
Description: This combined RR-FES treatment involves the same protocol as the RR regimen except that patients receive FES concurrently with RR.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Robotic Rehabilitation with PI
Description: The RR-PI protocol is the same as the RR-FES protocol described above except that the surface electrodes are attached to the same target muscles on the affected UL but there is no output of electrical stimulation.